185 related articles for article (PubMed ID: 35174076)
1. ASF1B: A Possible Prognostic Marker, Therapeutic Target, and Predictor of Immunotherapy in Male Thyroid Carcinoma.
Qiu W; Wu X; Shi H; Liu B; Li L; Wu W; Lin J
Front Oncol; 2022; 12():678025. PubMed ID: 35174076
[TBL] [Abstract][Full Text] [Related]
2. Construction of Novel lncRNA-miRNA-mRNA Network Associated With Recurrence and Identification of Immune-Related Potential Regulatory Axis in Hepatocellular Carcinoma.
Zhan T; Gao X; Wang G; Li F; Shen J; Lu C; Xu L; Li Y; Zhang J
Front Oncol; 2021; 11():626663. PubMed ID: 34336642
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Pan-Cancer Analysis and the Regulatory Mechanism of ASF1B, a Gene Associated With Thyroid Cancer Prognosis in the Tumor Micro-Environment.
Ma J; Han W; Lu K
Front Oncol; 2021; 11():711756. PubMed ID: 34490109
[TBL] [Abstract][Full Text] [Related]
4. ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma.
Zhang S; Xu L; Feng J; Tan D; Zhu Y; Hou J; Li W; Lv K; Wang W; Jiang L; Jiao M; Guo H
Front Genet; 2022; 13():842351. PubMed ID: 35360875
[No Abstract] [Full Text] [Related]
5. ASF1B Serves as a Potential Therapeutic Target by Influencing Cell Cycle and Proliferation in Hepatocellular Carcinoma.
Ouyang X; Lv L; Zhao Y; Zhang F; Hu Q; Li Z; Zhu D; Li L
Front Oncol; 2021; 11():801506. PubMed ID: 35087760
[TBL] [Abstract][Full Text] [Related]
6. The interaction between
Zhang Z; Liu S
Ann Med; 2023 Dec; 55(1):1111-1122. PubMed ID: 36947060
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of anti-silencing function 1B histone chaperone induces cell apoptosis via repressing PI3K/Akt pathway in prostate cancer.
Han G; Zhang X; Liu P; Yu Q; Li Z; Yu Q; Wei X
Int J Oncol; 2018 Nov; 53(5):2056-2066. PubMed ID: 30132513
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of ASF1B inhibits cell proliferation, migration, invasion and cisplatin resistance in gastric cancer through the Myc pathway.
Zhang Z; Ning M; Li L; Li Z; Wang Y; Zhao J
Oncol Lett; 2023 Jun; 25(6):242. PubMed ID: 37153049
[TBL] [Abstract][Full Text] [Related]
9. Anti-silencing function 1B knockdown suppresses the malignant phenotype of colorectal cancer by inactivating the phosphatidylinositol 3-kinase/AKT pathway.
Yu GH; Gong XF; Peng YY; Qian J
World J Gastrointest Oncol; 2022 Dec; 14(12):2353-2366. PubMed ID: 36568946
[TBL] [Abstract][Full Text] [Related]
10. Anti-silencing function 1B histone chaperone promotes cell proliferation and migration via activation of the AKT pathway in clear cell renal cell carcinoma.
Jiangqiao Z; Tao Q; Zhongbao C; Xiaoxiong M; Long Z; Jilin Z; Tianyu W
Biochem Biophys Res Commun; 2019 Mar; 511(1):165-172. PubMed ID: 30777326
[TBL] [Abstract][Full Text] [Related]
11. Carcinogenic Role and Clinical Significance of Histone H3-H4 Chaperone Anti-silencing Function 1 B (ASF1B) in Lung Adenocarcinoma.
Song C; Song Y; Wan X; Zhao Z; Geng Q
J Cancer; 2024; 15(1):218-231. PubMed ID: 38164276
[TBL] [Abstract][Full Text] [Related]
12. ASF1b is a novel prognostic predictor associated with cell cycle signaling pathway in gastric cancer.
Chen C; Bao H; Lin W; Chen X; Huang Y; Wang H; Yang Y; Liu J; Lv X; Teng L
J Cancer; 2022; 13(6):1985-2000. PubMed ID: 35399734
[TBL] [Abstract][Full Text] [Related]
13. ASF1B Promotes Oncogenesis in Lung Adenocarcinoma and Other Cancer Types.
Zhang W; Gao Z; Guan M; Liu N; Meng F; Wang G
Front Oncol; 2021; 11():731547. PubMed ID: 34568067
[TBL] [Abstract][Full Text] [Related]
14.
Li R; Cui X; Sun W; Yang Z; Shen X; Zhu C
Comb Chem High Throughput Screen; 2023; 26(7):1311-1323. PubMed ID: 35993469
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Analysis Identified ASF1B as an Independent Prognostic Factor for HBV-Infected Hepatocellular Carcinoma.
Wang X; Yi H; Tu J; Fan W; Wu J; Wang L; Li X; Yan J; Huang H; Huang R
Front Oncol; 2022; 12():838845. PubMed ID: 35280822
[TBL] [Abstract][Full Text] [Related]
16. Increased ASF1B Expression Correlates With Poor Prognosis in Patients With Gliomas.
Zhu H; Ouyang H; Pan X; Zhang Z; Tan J; Yu N; Li M; Zhao Y
Front Oncol; 2022; 12():912101. PubMed ID: 35875094
[TBL] [Abstract][Full Text] [Related]
17. Identification of ASF1B as a prognostic marker for liver cancer by meta-analysis and its immune value revealed by a comprehensive pan-cancer analysis of 33 human cancers.
Chen Y; Zhou W; Gong Y; Ou X
Prz Gastroenterol; 2023; 18(3):249-265. PubMed ID: 37937108
[TBL] [Abstract][Full Text] [Related]
18. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma.
Wang Q; Yu X; Zheng Z; Chen F; Yang N; Zhou Y
PeerJ; 2021; 9():e11342. PubMed ID: 33987018
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of pan-cancer reveals potential of ASF1B as a prognostic and immunological biomarker.
Hu X; Zhu H; Zhang X; He X; Xu X
Cancer Med; 2021 Oct; 10(19):6897-6916. PubMed ID: 34472711
[TBL] [Abstract][Full Text] [Related]
20. Anti‑silencing function 1B promotes the progression of pancreatic cancer by activating c‑Myc.
Zhang M; Zhang L; Zhou M; Wang E; Meng B; Li Q; Wang X; Wang Y; Li Q
Int J Oncol; 2023 Jan; 62(1):. PubMed ID: 36416310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
